Roslin, Ont. farmer faces insurance dispute after life-changing accident

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) shares moved into positive territory Wednesday, on word that the first patient has been randomized for its Phase 2 clinical study to evaluate the efficacy, safety, and tolerability of investigational compound NBI-1070770 in adults with major depressive disorder. NBI-1070770 is a novel, selective, and orally active, negative allosteric modulator (NAM) of the NR2B subunit-containing N-methyl-D-aspartate (NMDA NR2B) receptor.Said Chief Medical Officer Eiry Roberts, “Based upon our Phase 1 first-in-human study, we are excited to bring this novel oral…

The Goods from Steel & Oak Brewing Co. New Westminster, BC | Steel & Oak Brewing Co. is raising a glass to 12 years with the return of its annual anniversary party. An all-ages, community-driven celebration set to take over the brewery’s parking lot on Saturday, June 20th from 3:00 PM to 9:00 PM. The […]

Live music pulses through the air as Henry Leung casts a lure into the murky waters of the Lachine Canal at a site wedged between a noisy festival and the high-rises of Montreal’s Griffintown neighbourhood.